Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPhysical Medicine, Rehab & TherapiesAetna robotic-assisted rehabilitation Coverage | O…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0778

    Robotic-assisted Rehabilitation of the Extremities

    Customize your policy alerts

    Sign up for Aetna Policy 0778 alerts

    Get alerted when Policy 0778 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Aetna's coverage stance for robotic-assisted rehabilitation interventions and devices for upper and lower extremities, specifying which indications and devices are considered experimental/investigational and noting related policy cross-references. It affects providers submitting claims and prior authorization requests to Aetna.

    Policy Summary
    PayerAetna
    PolicyRobotic-assisted Rehabilitation of the Extremities
    Policy CodePolicy 0778
    Change TypeNo material change
    Effective DateMar 20, 2009
    Last ReviewOct 11, 2023
    Next Review DateAug 22, 2024
    Key ActionWhen requesting authorization, submit objective baseline impairment and functional measures and document a treatment plan specifying dose (e.g., >15 hours total training for upper‑limb gains) and active patient participation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    5Experimental indications listed
    08/22/2024Next review
    770MIT‑Manus RCT subjects
    2007Myomo e100 510(k)
    6 wksTypical RAGT program

    Coverage Criteria for Robotic-Assisted Rehabilitation

    inv-01: Experimental and Investigational Indications

    Not covered (experimental/investigational) for the following indications

    Experimental/Investigational Indications: Aetna considers robotic-assisted rehabilitation of the upper limb and lower limb experimental and investigational for the following indications because of insufficient evidence of effectiveness: humeral fracture; incomplete spinal cord injury; neuromuscular diseases (eg, cerebral palsy, multiple sclerosis, Parkinson disease); stroke; traumatic brain injury.

    List is not all-inclusive.

    inv-02: Experimental and Investigational Devices

    Devices/interventions considered experimental/investigational

    Experimental/Investigational Devices: Specific robotic interventions and devices considered experimental and investigational include the Intrepid Dynamic Exoskeletal Orthosis (IDEO), the Myomo e100 robotic arm brace, the Myomo MyoPro myoelectric limb orthosis, and powered hip orthoses for persons with spinal cord injury; effectiveness not established. The MyoPro/MyoMo myoelectric limb orthosis are considered exercise equipment by the FDA and most Aetna plans exclude exercise equipment.
    Policy Summary
    PayerAetna
    PolicyRobotic-assisted Rehabilitation of the Extremities
    Policy CodePolicy 0778
    Change TypeNo material change
    Effective DateMar 20, 2009
    Last ReviewOct 11, 2023
    Next Review DateAug 22, 2024
    Key ActionWhen requesting authorization, submit objective baseline impairment and functional measures and document a treatment plan specifying dose (e.g., >15 hours total training for upper‑limb gains) and active patient participation.
    SourceLink
    On This Page
    Coverage Criteria for Robotic-Assisted RehabilitationCoding and Billing ReferencesProvider Actions, Prior Authorization, and DocumentationBackground and Evidence OverviewDefinitions and Device Descriptions

    List is not all-inclusive.

    inv-03: Coverage criteria for electromechanical gait training

    Covered when ALL of the following align with evidence from RCTs and systematic reviews

    Population: Patient has acute or subacute neurologic impairment (eg, stroke within 3 months) or is non-ambulatory at intervention onset — populations in trials that derived benefit; greatest effect observed in early post-stroke and non-ambulatory patients.time since event <= 3 months OR non-ambulatory at baseline

    Based on planned subgroup and post-hoc analyses.

    Intervention: Electromechanical/robot-assisted gait training must be provided in combination with standard physiotherapy, with documented session frequency and duration comparable to trials (multiple sessions per week over several weeks).session frequency/duration similar to trials (eg, multiple sessions/week for several weeks)

    Trials combined RAGT with physiotherapy and showed increased odds of independent walking.

    Device and Program: Use of a specified, commercially available electromechanical or robotic gait device with a documented treatment protocol and therapist oversight consistent with trial descriptions.documented device and protocol

    Heterogeneity of devices and protocols in trials noted; device-specific claims should reference supporting RCTs.

    inv-04: Coverage criteria for robotic-assisted upper-limb training

    Covered when ALL of the following align with evidence for upper-limb robotic training

    Population: Patients after stroke with upper-limb paresis for whom intensive task practice is indicated; candidacy may favor those with some preserved hand/arm function depending on device-specific study populations (eg, ArmeoSpring).stage of recovery and baseline function per device study

    Subgroup findings suggest better candidacy for those with residual function.

    Intervention: Robotic-assisted arm training delivered with intensity and duration comparable to trials and matched or supplemented by conventional therapy as appropriate.intensity matched to comparator in trials (eg, total training dose comparable)

    Pooled trials showed improved ADLs and arm function when matched for therapy dose; variability in protocols noted.

    inv-05: Evidence summary and implications for coverage

    Key clinical findings from trials and economic analyses relevant to coverage decisions:

    Large randomized evidence: A multi-center RCT of 770 subjects (robot-assisted training vs EULT vs usual care) found no statistically significant improvement in upper limb functional recovery (ARAT success) for robot-assisted training compared with usual care or EULT; neither robot-assisted training nor EULT was cost-effective at common willingness-to-pay thresholds.

    Trial reported lack of functional benefit and unfavorable cost-effectiveness.

    Impairment vs functional outcomes: Robot-assisted training may reduce impairment (eg, improved Fugl-Meyer motor scores) but these impairment gains often did not translate into improvements in ADLs or functional recovery in trials.

    Impairment improvements noted but limited translation to ADL gains.

    Condition-specific signals: Some studies report benefits for gait symmetry, walking speed/distance, and balance in specific populations (eg, hemiplegic stroke, pediatric CP, certain SCI subgroups), but results are heterogeneous and limited by small samples or variable study designs.

    Evidence is mixed and condition-dependent.

    Adjunctive/experimental approaches: Adjuncts such as non-invasive brain stimulation or brain–computer interface–robot systems are early-stage or heterogeneous, and current evidence is insufficient to support consistent added benefit.

    Prototype/early clinical stage with heterogeneous reporting.

    inv-06: Coverage considerations and evidence synthesis

    Summary of evidence-based coverage considerations

    Evidence summary: Overall evidence is mixed: individual small trials report some benefits (eg, standing ability, walking speed/distance, reduced therapist assistance), but pooled meta-analyses frequently do not show superiority of RAGT or BWSTT over over-ground gait training; limitations include small sample sizes, heterogeneous protocols, and variable outcome reporting.

    Sources include pediatric RAGT reviews and BWSTT/RAGT vs over-ground systematic reviews.

    When to consider robotic-assisted therapy: Consider RAGT or powered orthoses as adjuncts within a multimodal rehabilitation program when conventional therapies have been insufficient and when there is ability to monitor and document objective functional outcomes and adverse events.

    Supported by recommendations to monitor individual progress and by studies showing potential adjunctive benefits in select populations.

    Research/experimental stance: For many indications (eg, pediatric non-CP diagnoses, certain IDEO applications in civilian settings, some powered orthosis designs), evidence is insufficient and clinical use should be within structured programs or research contexts pending higher-quality studies.

    Further high-quality trials are needed.

    inv-07: Situations with evidence-supported benefit

    Evidence suggests benefit under specific conditions:

    RAGT benefits in SCI: Robot-assisted gait training may improve gait functional parameters in subacute incomplete spinal cord injury (eg, AIS-C) compared with dynamic parapodium training; benefit observed in studies of subacute incomplete SCI.subacute phase; incomplete SCI

    Single-center trial (Tarnacka et al) showed greater MS and WISCI-II improvements in incomplete SCI with RAGT.

    RAT benefits in stroke with sufficient dose: Robot-assisted upper limb therapy can produce small but significant immediate improvements in motor control and activity function post-stroke compared with non-robotic therapy when total training time exceeds 15 hours and patients actively participate, though benefits may not persist at follow-up.> 15 hours total training; patient active participation

    Meta-analysis (Zhang et al 2022) found small SMDs for FM-UE and activity post-intervention when total training time >15 hours; effects not sustained at follow-up.

    Home-based O-RAGT vascular and activity benefits: Home-based overground RAGT combined with usual care increased physical activity and improved vascular measures (eg, reduced carotid–femoral pulse wave velocity) in chronic stroke survivors in a 10-week program.10-week program in chronic stroke

    Randomized trial reported maintained cfPWV improvement at 3 months.

    inv-08: Evidence not supporting routine use

    High-quality RCT evidence showing no superiority:

    MIT-Manus multi-center RCT: In a large multi-center randomized trial of 770 participants, robot-assisted training (MIT-Manus/InMotion system) did not improve upper limb functional recovery (ARAT success) compared with usual care or enhanced upper-limb therapy (EULT); the study concluded robot-assisted training as delivered in the trial should not be used routinely in clinical practice.patients 1 week to 5 years post-stroke; 45 min sessions 3x/week for 12 weeks

    Higher serious adverse events were observed in robot and EULT arms though none attributable to the interventions.

    The Myomo MyoPro myoelectric limb orthosis and similar myoelectric/robotic arm braces are classified in this policy as exercise equipment and are listed among devices considered experimental and investigational because their effectiveness for medical purposes has not been established. As noted, the Myomo MyoPro is regarded as exercise equipment by the FDA and most Aetna benefit plans exclude coverage for exercise equipment, so routine coverage should not be assumed.

    Routine provision of body-weight–supported treadmill training (BWSTT) or robotic-assisted step training (RAST) in place of progressive, matched-intensity over‑ground training is discouraged outside of scientifically conducted efficacy trials. Systematic reviews and expert summaries conclude BWSTT/RAST have not consistently demonstrated superior outcomes compared with equivalent-dose progressive over‑ground training, and therefore should not replace conventional over‑ground therapy as a routine practice.

    Economic analyses and a large multicenter trial indicate that some robotic-assisted interventions were unlikely to be cost‑effective at commonly used willingness‑to‑pay thresholds. Where an intervention lacks favorable cost‑effectiveness at standard WTP levels, payers may apply utilization management or limit coverage of that intervention unless strong, individualized clinical justification and outcome monitoring are documented.

    The Intrepid Dynamic Exoskeletal Orthosis (IDEO) is a customized, energy‑storing ankle–foot orthosis developed for severe lower‑extremity injury, but current evidence is insufficient to support its generalized clinical value outside the structured integrated orthotic‑rehabilitation programs studied. Use of IDEO in routine civilian practice therefore remains experimental and investigational unless provided within defined protocols with prospective outcome measurement.

    Published evidence highlights several mechanical and physiologic limitations of robot‑assisted gait training (RAGT), including abnormal sensory stimuli from straps, reduced muscle activation, passively induced movements, limited trunk/pelvis movement, and altered foot pressure patterns. These device‑ and technique‑related limitations may reduce the ability of RAGT to produce normal gait patterns or expected functional gains in some spinal cord injury and other patient populations.

    Available guideline and review sources do not list robotic‑assisted rehabilitation among recommended management options for proximal or midshaft humeral fractures. UpToDate reviews cited in the policy on proximal and midshaft humeral fractures do not mention robotic‑assisted rehabilitation, implying a lack of guideline endorsement for this indication.

    This Clinical Policy Bulletin provides a partial, general description of Aetna plan benefits and is intended to assist in administering benefits; it does not guarantee coverage. The bulletin is not a contract or medical advice, and coverage determinations remain subject to individual plan terms and documented medical necessity.

    Robotic‑assisted gait training for chronic or ambulatory patients has shown limited and inconsistent evidence of superiority over equivalent‑dose conventional over‑ground training. Systematic reviews and RCT summaries report no reliable advantage for routine use in chronic or ambulatory populations; therefore routine authorization for such patients should be supported by individualized evidence of likely benefit and objective outcome measures.

    In a large multicenter randomized trial of 770 participants the robot‑assisted upper‑limb program did not improve upper‑limb functional recovery (ARAT success) compared with usual care or an enhanced upper‑limb therapy (EULT) program, and economic evaluation found robot‑assisted training to be the most costly option with low probability of cost‑effectiveness at typical WTP thresholds. Given these findings, robot‑assisted training as delivered in that trial did not demonstrate added functional benefit or favorable value compared with usual care.

    Pooled evidence indicates that RAGT and BWSTT provided solely to increase walking speed or distance do not reliably outperform comparable over‑ground gait training. Meta‑analyses and systematic reviews report no consistent superiority for walking speed or distance, so using RAGT/BWSTT only for marginal gains in speed/distance over conventional training is not supported by the evidence.

    Protocols identical to those used in the MIT‑Manus multi‑center trial (45‑minute sessions, three times weekly for 12 weeks) did not demonstrate superiority over usual care or EULT for upper‑limb functional recovery in the trial population. Therefore, replication of that exact protocol for routine clinical coverage is not supported without evidence of individualized benefit.

    The body of evidence is limited by methodological issues in multiple studies, including small sample sizes, lack of blinding, and absence of control groups in several reports. These limitations constrain confidence in effect estimates and underline the need for larger, well‑controlled randomized trials before routine coverage can be broadly endorsed.

    This portion of the policy does not enumerate explicit clinical conditions that are designated 'not medically necessary.' Instead, it identifies interventions and devices considered experimental or investigational and emphasizes that coverage decisions depend on plan terms, documented medical necessity, and alignment with the available evidence.

    Coding and Billing References

    HCPCS codes listedHCPCS
    L8701Powered upper extremity range of motion assist device, elbow, wrist, hand with single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated.
    L8702Powered upper extremity range of motion assist device, elbow, wrist, hand, finger, single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated.
    ICD-10 codes mentioned (not covered for indications listed)ICD-10Not Covered
    G20 - G21.9Parkinson's disease.
    G35Multiple sclerosis.
    G70.00 - G70.9Myasthenia gravis and other myoneural disorders.
    G73.1 - G73.3Other specified myoneural disorders.
    G80.0 - G80.2 G80.4 - G80.9Cerebral Palsy.
    I69.031 - I69.069 I69.131 - I69.169 I69.231 - I69.269 I69.331 - I69.369 I69.831 - I69.869 I69.931 - I69.969Sequelae of cerebrovascular disease, monoplegia, hemiplegia and hemiparesis, and other paralytic syndrome.
    S06.0X0A - S06.A1XSTraumatic brain injury.
    S14.101+ - S14.149, S14.151+ - S14.159+, S24.101+ - S24.119, S24.131+ - S24.149+, S24.151+ - S24.159+, S34.101+ - S34.119+, S34.121+ - S34.129+, S34.131+, S34.132, S34.139+Incomplete lesion of spinal cord.
    S42.201A - S42.296SFracture of upper end of humerus.
    Total training time for upper-limb benefit
    Total training time threshold> 15 hours total training when targeting upper-limb gains
    Evidence sourceZhang et al (2022) meta-analysis: benefits for FM-UE and activity function observed only when total training time > 15 hours
    Implication for prior authorizationRequire documented treatment plan showing >15 hours total robot-assisted upper-limb training to support expected immediate motor control/activity gains
    LimitationsImprovements observed at end of treatment but not sustained at follow-up in pooled data

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    PA: alignment with evidence (gait training)

    Prior authorization: Electromechanical-assisted gait training (including robotic-assisted gait training, Lokomat, and similar devices) is most supported when provided in combination with physiotherapy and structured gait-training programs. Prior authorization should require documentation that the intervention will be delivered as part of a combined physiotherapy program (not as a standalone modality).

    • Require description of planned combined physiotherapy and device-based sessions (frequency, duration, therapy type).
    • PA should note patient’s ambulatory status and timing relative to stroke onset (acute/non-ambulatory patients derive most benefit).
    Documentation Required

    Structured program documentation for IDEO

    When Intrepid Dynamic Exoskeletal Orthosis (IDEO) or similar integrated orthotic-and-rehabilitation programs are used, prior authorization or documentation should include enrollment in a structured, integrated program (for example, 'Return to Run') and evidence of participation in the specified protocol.

    • Provide program name, start date, expected duration, and therapy schedule.
    • Include baseline and interim functional testing as part of the program.
    Prior Authorization

    Objective measures, treatment dose and participation required

    Prior authorization and clinical documentation should include objective baseline measures, planned treatment dose, and intended outcome measures. Submission of these elements is required for review.

    • Baseline measures: neurologic level, functional status (WISCI, FAC, SCIM, AIS, NIHSS, ARAT, FM-UE, DASH, WMFT-O as applicable).
    • Planned treatment dose: total number of sessions, duration per session, therapy frequency, total training hours (note: many studies identify >15 hours as associated with measurable UL effects).
    • Planned outcome measures and timing of follow-up assessments.
    Note

    Prior authorization not specified

    No explicit prior authorization requirements are specified elsewhere in this document segment for some devices and indications. Providers should follow local plan rules; absence of an explicit PA requirement in this bulletin does not guarantee coverage.

    • Check member-specific benefit plan for PA rules and coverage exclusions (e.g., exercise equipment exclusions for MyoPro).
    Denial Risk

    Experimental and Investigational indications

    Robotic-assisted rehabilitation for the upper and lower limb is considered experimental and investigational for listed indications due to insufficient evidence of effectiveness. Coverage is not supported for these indications unless plan language allows or additional evidence is provided.

    • Noted indications: humeral fracture; incomplete spinal cord injury; neuromuscular diseases (cerebral palsy, multiple sclerosis, Parkinson disease); stroke; traumatic brain injury.
    • Specific devices labeled investigational: IDEO, Myomo e100, Myomo MyoPro, powered hip orthoses.
    Denial Risk

    Risk from deviation from studied protocols

    Providing electromechanical-assisted gait training outside the combined physiotherapy protocols evaluated in trials may not achieve the same benefits seen in studies. Risk of providing therapy that deviates from studied protocols should be considered when authorizing or billing.

    • Document how planned intervention adheres to the protocols (session length, combined PT content) used in supporting studies.
    • If deviation is planned, provide rationale and supporting evidence.
    Denial Risk

    Cost-effectiveness may affect coverage

    Cost-effectiveness findings from large RCTs and health economic analyses may affect coverage decisions. Interventions that are not cost-effective at common willingness-to-pay thresholds may be subject to limitation or denial.

    • Document expected resource use and alternative lower-cost therapy options.
    • Be aware that robot-assisted training was not cost-effective compared with usual care or EULT in cited trials.
    Denial Risk

    Insufficient evidence for pediatric RAGT

    Evidence for pediatric robotic-assisted gait training (RAGT) is limited and inconsistent, particularly outside cerebral palsy. Insufficient evidence for pediatric RAGT may lead to denial if medical necessity is not clearly established.

    • If used in children, submit pediatric-specific outcomes, monitoring plans, and adverse event surveillance.
    • Identify diagnosis-specific evidence supporting the proposed RAGT use.
    Denial Risk

    Lack of demonstrated benefit in RCT

    A large multicenter RCT did not demonstrate improved upper limb functional recovery with robot-assisted training versus usual care or enhanced upper limb therapy (EULT); robot-assisted training was not cost-effective. These findings support careful authorization and documentation requirements.

    • For upper limb robot-assisted programs, require justification showing how proposed use differs from programs evaluated in the RCT or how it will address identified limitations.
    • Include plans to measure clinically meaningful functional outcomes (ARAT, FM-UE, ADL measures).
    Note

    None specified in this excerpt

    No additional provider-action items are specified in this excerpt beyond the documentation, PA alignment with evidence, and investigational listings noted above.

    • Follow plan-specific medical necessity and PA rules for device-based rehabilitation.
    Note

    Administrative disclaimer

    Administrative: Clinical Policy Bulletins are intended to assist in administering plan benefits and are not guarantees of coverage. Providers must confirm member-specific benefits and follow plan procedures for prior authorization and claims submission.

    • Clinical Policy Bulletins provide partial descriptions of benefits and do not constitute a contract.
    • Providers remain responsible for medical advice and treatment; verify coverage and PA requirements with the payer.
    Documentation Required

    Suggested supporting documentation

    Suggested supporting documentation: Include device-specific justification, objective baseline and planned outcome measures, and evidence that the intervention is part of a structured therapeutic program when applicable.

    • Device description and FDA status (clearance/510(k) vs. exercise equipment designation).
    • Rationale linking device use to specific deficits and expected functional gains.
    Documentation Required

    Required clinical documentation elements

    Required clinical documentation elements: Document baseline neurologic level, functional status measures (WISCI, FAC, SCIM, AIS, NIHSS, ARAT, FM-UE, DASH, WMFT-O), cognition, pain, gait speed, and ADL status as applicable.

    • Provide dates and scores for baseline assessments and planned follow-up timepoints.
    • If trial protocol exists, submit the protocol and intended follow-up schedule.
    Documentation Required

    Outcome and cost documentation

    Outcome and cost documentation: Trials demonstrated limited translation of impairment gains into functional improvement and higher costs for robot-assisted training. Providers should document anticipated outcomes and expected resource use.

    • Include projected functional endpoints (e.g., ARAT improvement, walking speed, 6MWT) and cost estimates for the proposed program.
    • Report prior therapies and response to date to show incremental benefit expected from the device-based intervention.
    Documentation Required

    Outcome measure and AE documentation

    Outcome measures and adverse event (AE) documentation should be included with any authorization or claims: report baseline and post-intervention measures (standing ability, 6MWT, TUG, ARAT, FM-UE, DASH, WMFT-O), and document any AEs.

    • Specify timing of post-intervention assessments and define criteria for clinical success.
    • List any device-related AEs and serious AEs, and indicate attribution to intervention.
    Documentation Required

    Required clinical outcome documentation

    Required clinical outcome documentation for upper limb robotic trials commonly includes DASH, WMFT-O, ROM, pain scales, cognition assessments, and ARAT/FM-UE. Ensure these are included when relevant.

    • Provide numeric scores and change from baseline for each outcome measure at defined follow-up points.
    • If long-term follow-up is planned, provide schedule and method (in-person, postal, or phone).
    Documentation Required

    Study protocols and clinical follow-up

    Study protocols and clinical follow-up: Trials frequently included baseline assessments (cognition, pain, ability to work, gait speed, ARAT, DASH, ROM, WMFT-O) and predefined follow-up timepoints (post-intervention, 3 months, 6 months, 12 months). Provide equivalent follow-up plans when requesting authorization.

    • Specify baseline and follow-up assessments, measurement tools, and timing.
    • Indicate who will conduct assessments (blinded assessor when feasible).
    Note

    Policy bulletin use

    Policy bulletin use: Clinical Policy Bulletins assist in administering plan benefits and provide partial descriptions; they do not guarantee coverage. Verify member-specific benefits and plan rules.

    • This bulletin does not constitute a contract or coverage guarantee.
    • Providers must follow payer-specific PA and claims processes.
    Step Therapy

    Prior conventional therapy and step therapy preference

    Prior conventional therapy and step therapy recommendations: Evidence suggests therapist-assisted locomotor training or progressive over-ground training (OGT) may be as effective or superior to robotic-assisted approaches for some outcomes. Consider requiring a trial of conventional therapy or equivalent-intensity upper-limb therapy (EULT) before approving robotic-assisted programs.

    • Require documentation of prior conventional gait or upper-limb therapy (dates, frequency, objective response) unless contraindicated or not feasible.
    • If step therapy is not required by plan, note that evidence supports RAGT as adjunctive rather than first-line replacement therapy.
    Step Therapy

    Conventional therapy prior to RAGT; RAGT as adjunctive therapy

    Conventional therapy prior to RAGT and RAGT as adjunctive therapy: Given mixed evidence, RAGT should generally be considered adjunctive to multi-modal rehabilitation rather than a substitute for conventional therapies.

    • Document concurrent rehabilitation modalities and therapist involvement (percent of session with active therapist input).
    • Describe how RAGT will be integrated into the overall rehabilitation plan.
    Note

    No step therapy requirements are described

    No routine step therapy requirements are described in this bulletin; however, payers may implement step-wise requirements per plan. Providers should confirm if step therapy (conventional therapy trial) is required prior to authorization.

    • If no step therapy is in force, still provide documentation of prior therapy and rationale for proceeding to device-based rehabilitation.

    Background and Evidence Overview

    Stroke is a leading cause of long‑term disability; more than half of patients with post‑stroke upper‑limb paresis have persistent arm impairment. This clinical context underlies consideration of robotic and myoelectric devices as potential aids for rehabilitation, while also noting that current evidence for many robotic interventions remains mixed or preliminary.

    Definitions and Device Descriptions

    Myoelectric orthotic device / Myomo e100
    DeviceMyomo e100 electromechanically powered elbow brace (wearable), intended to facilitate arm movement and increase ROM
    MechanismUses surface EMG sensors to detect resting muscle potential and provides a motorized power boost to assist desired motion in real time
    Regulatory statusReceived 510(k) marketing clearance in April 2007
    Intended useDesigned as part of prescribed physical therapy to enable stroke patients to exercise when they cannot independently do so
    Experimental and investigational — Definition
    DefinitionInterventions or devices for which effectiveness is insufficiently established and therefore considered experimental/investigational by Aetna
    Examples (policy)IDEO, Myomo e100 robotic arm brace, Myomo MyoPro myoelectric limb orthosis, powered hip orthoses for SCI
    Coverage implicationDevices/uses labeled experimental/investigational are not covered and may be denied absent high-quality supporting evidence
    Electromechanical/robot-assisted gait training (RAGT)
    DefinitionAutomated treadmill-based or end-effector devices, often with body-weight support, that assist stepping patterns to provide repetitive gait training
    Typical program elementsUsed in combination with physiotherapy; sessions repeated over weeks as studied in RCTs
    Expected benefits per evidenceIn combination with physiotherapy, increased odds of independent walking in stroke trials though not consistently improving walking speed or capacity
    Electromechanical/robot-assisted arm training
    DefinitionRobotic devices for upper‑limb therapy designed to deliver repetitive, task‑oriented movements to improve arm function and ADLs after stroke
    Evidence summaryCochrane review (19 trials, 666 participants) showed improvements in ADLs and arm function but heterogeneity in duration, amount of training, device types
    Program considerationsEffectiveness may depend on training intensity/duration and patient characteristics (residual function)
    Robot-assisted gait training (RAGT)
    DefinitionUse of robotic systems (e.g., Lokomat, end-effector systems, exoskeletons) to provide assisted walking practice, often with programmable gait trajectories and body-weight support
    Device examplesLokomat, end-effector systems, driven gait orthoses, overground robotic walkers
    Limitations notedPotential for abnormal sensory stimuli from straps, reduced muscle activation, passive movements, and limited trunk/pelvis movement may constrain functional gains
    EULT (Enhanced Upper Limb Therapy)
    DefinitionProgram of repetitive functional task practice focused on upper-limb use used as an active comparator in trials (EULT)
    Clinical roleEULT has shown comparable or superior outcomes to robot-assisted training in large RCTs (e.g., MIT-Manus trial), supporting stepwise use of conventional/enhanced therapy before robotics
    Use in trialsTypically delivered at matched intensity/duration to robotic arms to assess comparative effectiveness
    IDEO — Intrepid Dynamic Exoskeletal Orthosis
    DeviceIntrepid Dynamic Exoskeletal Orthosis (IDEO): customized energy‑storing ankle‑foot orthosis with a calf strut and cuff
    Intended functionDesigned to supply energy storage and return capabilities to injured ankles to support high‑level activities
    Evidence stanceCurrently insufficient evidence to support broad civilian clinical use outside structured integrated programs
    Powered orthoses / PHO
    DefinitionPowered hip orthoses and powered gait orthoses are externally powered devices (electric, pneumatic, hydraulic) intended to induce movement patterns and assist gait training
    Target populationInvestigated for persons with spinal cord injury to improve gait kinematics and temporal‑spatial parameters
    Evidence statusPreliminary studies show kinematic/temporal improvements but further research needed to confirm long‑term rehabilitative benefit
    RAT (robot-assisted therapy)
    DefinitionRobotic devices and protocols aimed at repetitive, task‑specific upper‑limb training (exoskeletal or end‑effector systems) to improve motor control and activity
    Evidence noteMeta-analyses show small immediate benefits in FM-UE and activity function, often dependent on total training dose (>15 hours)
    Clinical implicationActive patient participation and adequate dose increase likelihood of short‑term gains; long‑term benefits not consistently demonstrated
    RAGT (robot-assisted gait training) — general
    DefinitionRobotic systems delivering overground or treadmill-based gait training intended to improve temporal‑spatial gait parameters and walking function
    Device examplesLokomat, end‑effector systems, driven gait orthoses, overground robotic walkers
    Program roleOften used adjunctively with conventional gait rehabilitation; evidence supports incorporation into multimodal programs rather than replacement
    Myoelectric elbow-wrist-hand orthosis (MEWHO) / MyoPro
    DeviceMyoelectric elbow‑wrist‑hand orthosis (MEWHO) / MyoPro: custom myoelectric orthosis using surface EMG sensors to detect voluntary signals and assist impaired arm movement
    Intended useUsed as assistive device and as a tool in motor learning–based therapy; pilot studies report clinically meaningful Fugl‑Meyer gains with intensive in‑clinic programs
    Evidence needsCurrent data are from small pilot/interventional studies without controls; randomized trials needed to confirm effectiveness
    ArmeoSpring
    DeviceArmeoSpring: a robotic arm support device used adjunctively with occupational therapy
    Study findingsSmall RCT (Taveggia et al) showed robot-assisted mobilization with PRM was as effective as traditional rehabilitation for pain, disability and spasticity in upper‑limb post‑stroke patients
    LimitationsEvidence from small samples and short follow‑up; further validation required
    Clinical Policy Bulletin
    DefinitionClinical Policy Bulletin: Aetna‑developed document to assist administering plan benefits; not an offer of coverage or medical advice and does not constitute a contract
    Administrative noteContains partial descriptions of plan benefits; actual coverage depends on individual plan terms and evidence
    Policy metadataPolicy number 0778; Last review 10/11/2023; Effective 03/20/2009; Next review 08/22/2024